Company / Depreciation & Amortization
Arrowhead Pharmaceuticals Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$22.2M
FY2025
5-year range
$4.2M / $22.2M
FY2021-FY2025
Trend
+31.4%
vs FY2024
Sector context
#44 of 168
Health Care
What the data says
At $22M, Arrowhead Pharmaceuticals's depreciation & amortization ranks #125 of 168 in the Health Care sector. Depreciation & Amortization has increased for 3 consecutive years, from $4M in FY2022 to $22M in FY2025.
Based on SEC 10-K filings.
$22M in FY2025 with a 5-year CAGR of +39.5%.
Increased from $7M to $22M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +74.2%
- 5-Year CAGR
- +39.5%
- 10-Year CAGR
- -
Sector benchmark
#125 of 168 in Health CareTop 74% of 168This company $22.2M Sector average $212.9M
▼
-89.6% below sector average
Key checks
Key Insights
- Arrowhead Pharmaceuticals's depreciation & amortization has grown for 3 consecutive years.
- 5-year CAGR of +39.5%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 31.4% year-over-year.
- Ranks #44 out of 168 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $22.2M | +31.4% |
| FY2024 | $16.9M | +156.1% |
| FY2023 | $6.6M | +57.1% |
| FY2022 | $4.2M | -36.4% |
| FY2021 | $6.6M | +57.1% |
| FY2020 | $4.2M | +40.5% |
| FY2019 | $3.0M | -8.3% |
| FY2018 | $3.3M | +39.5% |
| FY2017 | $2.3M | -28.3% |
| FY2016 | $3.3M | +86.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026